Close



Apr 15, 2024 08:32AM
Apr 15, 2024 08:30AM
Apr 9, 2024 12:00PM
Apr 9, 2024 11:59AM
Apr 1, 2024 04:00PM
Mar 19, 2024 08:31AM
Mar 19, 2024 08:30AM Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Mar 18, 2024 08:33AM
Mar 18, 2024 08:30AM
Mar 12, 2024 08:32AM
Mar 12, 2024 08:30AM
Mar 6, 2024 08:30AM
Feb 22, 2024 08:30AM
Feb 7, 2024 08:30AM Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Jan 9, 2024 08:31AM
Jan 9, 2024 08:30AM
Dec 18, 2023 09:00AM
Dec 4, 2023 08:30AM
Nov 20, 2023 08:30AM
Nov 13, 2023 09:00AM
Nov 9, 2023 09:01AM Atossa Therapeutics (ATOS) Appoints Jonathan Finn to its Board
Nov 9, 2023 09:00AM
Oct 30, 2023 01:00PM
Oct 17, 2023 08:00AM
Oct 11, 2023 08:30AM
Aug 14, 2023 08:30AM
Aug 8, 2023 09:00AM
Jul 20, 2023 09:15AM Atossa Therapeutics (ATOS) Approved in Canada to Conduct Phase 2 EVANGELINE Trial
Jul 20, 2023 09:15AM
Jul 13, 2023 04:16PM
Jul 13, 2023 04:15PM
Jul 10, 2023 09:15AM
Jul 6, 2023 09:15AM
Jul 6, 2023 09:15AM
Jun 28, 2023 09:15AM Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Jun 27, 2023 09:15AM
Jun 27, 2023 09:15AM
Jun 22, 2023 04:15PM
Jun 21, 2023 10:15AM
Jun 21, 2023 10:13AM
Jun 14, 2023 09:15AM
Jun 12, 2023 09:15AM Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Jun 1, 2023 09:10AM
May 23, 2023 07:00AM
May 15, 2023 09:10AM
May 11, 2023 09:00AM
May 9, 2023 09:15AM
Apr 27, 2023 09:15AM
Mar 22, 2023 04:07PM Atossa Therapeutics (ATOS) Reports FY22, Provides Corporate Update
Mar 22, 2023 04:05PM

251,872 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All